Global Rheumatoid Arthritis Market, By Diagnosis (Blood test, Physical examination and Imaging Test), Treatment (Medication, Therapy and Surgery), Route of Administration (Oral, Subcutaneous and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.
Rheumatoid Arthritis Market Analysis and Size
The global rheumatoid arthritis market is expected to witness significant growth during the forecast period. Rheumatoid arthritis affects the performance of daily activities, including household tasks and work, and also results in mortality. People who smoke frequently are at high risk of getting rheumatoid arthritis. Worldwide, leading companies are maintaining their market position by acquiring companies that are facing a large number of product recalls. Furthermore, favorable reimbursement policies and increasing healthcare expenditure are some other factors driving market expansion.
Data Bridge Market Research analyses a growth rate in the global rheumatoid arthritis market in the forecast period 2022-2029. The expected CAGR of global rheumatoid arthritis market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 45.6 billion in 2021, and it would grow upto USD 69.98 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Rheumatoid Arthritis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Blood test, Physical examination and Imaging Test), Treatment (Medication, Therapy and Surgery), Route of Administration (Oral, Subcutaneous and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Rheumatoid arthritis is a type of chronic inflammatory, an autoimmune disorder in which one can affect joint and several other body parts such as skin, eyes, lungs and blood vessels. Rheumatoid arthritis affects the lining of joints, leading to a painful inflammation which can eventually result in bone erosion and joint deformity.
Global Rheumatoid Arthritis Market Dynamics
Drivers
- High Prevalence of Arthritis
Its been witnessed that more than 350 million people have arthritis all over the globe. In the U.S., 1 in 4 adults have been reported with arthritis in 2020. It’s estimated to be 78 million by the year 2040. This boosts the market growth.
- Growing advancements in biologics
All contributing factors are the advances in advanced biologics, increased purchasing power, increased healthcare expenditure, and worldwide access to high-quality medications for middle- and poor-class families. On the other hand, the global rheumatoid arthritis drugs market is predicted to increase quickly due to enhanced treatment regarding early treatment and screening of rheumatoid arthritis and shift the market outlook. As a result, growing advancements in biologics is creating lucrative opportunities for the growth of global rheumatoid arthritis drugs market.
Opportunities
- Increase in Elderly Population
Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies.
- Increased Clinical Research
Recent pre-clinical investigations have shown that combination is significantly capable of decreasing joint pathology in the murine experimental arthritis model. Therefore, a future combination of TNF inhibitors with an anti-IL-17 antibody seems plausible. Furthermore, new era of bi-specific antibodies is projected to push market growth during the forecast period
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform the treatments could curb the growth of the global rheumatoid arthritis market over a forecast period.
- High Cost
The huge expenditure required for treatment process hamper the market growth. The treatment of RA involves a varied range of treatment processes including different therapy types, diagnostic procedures and much kore. Thus, it impedes the growth of the market.
This global rheumatoid arthritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global rheumatoid arthritis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
In 2020, Mylan announced that the FDA approved Hulio, a biosimilar to Humira (adalimumab, AbbVie). It is a TNF inhibitor intended to treat patients with rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis.
Global Rheumatoid Arthritis Market Scope
The global rheumatoid arthritis market is segmented on the basis of diagnosis, treatment, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Blood test
- Physical examination
- Imaging Test
Treatment
- Medication
- Therapy
- Surgery
Route of Administration
- Oral
- Subcutaneous
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Rheumatoid Arthritis Market Regional Analysis/Insights
The global rheumatoid arthritis market is analyzed and market size insights and trends are provided by diagnosis, treatment, route of administration, end-user and distribution channel as referenced above.
The major countries covered in the global rheumatoid arthritis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to latest technology development and presences of variety of innovative drug molecule to enhance the treatment procedure.
Asia-Pacific is expected to account for the largest market share due to increased prevalence of inflammatory disorders and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Rheumatoid Arthritis Market Share Analysis
The global rheumatoid arthritis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global rheumatoid arthritis market
Key players operating in the global rheumatoid arthritis market include:
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- Ampio Pharmaceuticals Inc. (U.S.)
- Lilly (U.S)
SKU-